A Japanese early clinical experience explored the effect of Atezolizumab plus Bevacizumab (ATZ/BV) in HCC patients harbouring CTNNB1 Mutation and found that ATZ/BV might improve the immunosuppressive tumour microenvironment caused by CTNNB1 mutation [45]. The gene discussed is CTNNB1; the disease is neoplasm.